High levels of PGM3 mRNA correlate with poor prognosis in not only NSCLC and breast cancer [26] but also bladder cancer in a human cohort (Figure 6I,J), suggesting that FR054 treatment may have therapeutic potential for a broader range of tumor types. This evidence concerns the gene PGM3 and urinary bladder cancer.